Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2025)

Lyell Immunopharma's Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 45.17% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $14.2 million, down 27.94%, while the annual FY2024 figure was $19.6 million, 3.06% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $2.6 million at Lyell Immunopharma, down from $3.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.1 million in Q3 2023 and bottomed at $2.0 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $4.6 million (2022), against an average of $4.2 million.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 270.56% in 2021 before it tumbled 45.17% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $4.6 million in 2021, then increased by 10.43% to $5.0 million in 2022, then grew by 0.32% to $5.1 million in 2023, then dropped by 0.61% to $5.0 million in 2024, then tumbled by 48.95% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Depreciation & Amortization (CF) are $2.6 million (Q3 2025), $3.1 million (Q2 2025), and $3.4 million (Q1 2025).